Send to

Choose Destination
Ther Clin Risk Manag. 2012;8:323-8. doi: 10.2147/TCRM.S30139. Epub 2012 Jun 22.

Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).

Author information

Wiwanitkit House, Bang Khae, Bangkok, Thailand.


Leishmaniasis is an important vector-borne disease, and it is classified as one of the most important tropical fly-borne infections. This disease can cause two types of clinical manifestations: cutaneous forms and visceral forms. Visceral leishmaniasis, which is also called kala-azar, is a very serious infection that can be fatal. The management of visceral leishmaniasis requires informed diagnostic and therapeutic approaches. Continuous research and development regarding the treatment of visceral leishmaniasis had led to many improvements. Paromomycin is a relatively new antibiotic drug that has been used for the treatment of visceral leishmaniasis for several years. This article reviews and discusses the use of paromomycin for visceral leishmaniasis therapy.


leishmaniasis; paromomycin; visceral

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center